Syndax Pharmaceuticals (SNDX) Tops Q4 EPS, Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update
March 1, 2022 4:05 PM ESTWALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2021. In addition, the Company provided a clinical and business update.
"2021 was marked by substantial progress advancing our pipeline of novel cancer therapies, including the initiation of our two pivotal programs for which we expect to report topline data starting in the first half of 2023," said Michael A. Metzger, Chief Executive Officer. "We... More
